JP2022501334A5 - - Google Patents
Info
- Publication number
- JP2022501334A5 JP2022501334A5 JP2021513960A JP2021513960A JP2022501334A5 JP 2022501334 A5 JP2022501334 A5 JP 2022501334A5 JP 2021513960 A JP2021513960 A JP 2021513960A JP 2021513960 A JP2021513960 A JP 2021513960A JP 2022501334 A5 JP2022501334 A5 JP 2022501334A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- salt
- alkoxy
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730611P | 2018-09-13 | 2018-09-13 | |
| US62/730,611 | 2018-09-13 | ||
| PCT/US2019/050721 WO2020056074A1 (en) | 2018-09-13 | 2019-09-12 | Indazole carboxamides as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501334A JP2022501334A (ja) | 2022-01-06 |
| JP2022501334A5 true JP2022501334A5 (enExample) | 2022-09-05 |
| JP7434294B2 JP7434294B2 (ja) | 2024-02-20 |
Family
ID=68073172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513960A Active JP7434294B2 (ja) | 2018-09-13 | 2019-09-12 | キナーゼ阻害剤としてのインダゾールカルボキサミド |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12084426B2 (enExample) |
| EP (1) | EP3849969B1 (enExample) |
| JP (1) | JP7434294B2 (enExample) |
| KR (1) | KR102793119B1 (enExample) |
| CN (1) | CN112673001B (enExample) |
| AU (1) | AU2019339355A1 (enExample) |
| BR (1) | BR112021004310A2 (enExample) |
| CA (1) | CA3112519A1 (enExample) |
| EA (1) | EA202190759A1 (enExample) |
| ES (1) | ES2945220T3 (enExample) |
| IL (1) | IL281371A (enExample) |
| MX (1) | MX2021002617A (enExample) |
| SG (1) | SG11202102406XA (enExample) |
| WO (1) | WO2020056074A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3704118T3 (da) | 2017-10-30 | 2022-03-14 | Bristol Myers Squibb Co | Aminoimidazopyrazin som kinasehæmmere |
| SG11202007035YA (en) | 2018-01-26 | 2020-08-28 | Bristol Myers Squibb Co | Aminopyrrolotriazines as kinase inhibitors |
| EP3849968B1 (en) | 2018-09-13 | 2022-12-21 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| EP3849969B1 (en) | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2021067654A1 (en) * | 2019-10-03 | 2021-04-08 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| KR20230100646A (ko) | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| CA2591817A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| PL2018380T3 (pl) | 2006-05-19 | 2012-05-31 | Abbvie Bahamas Ltd | Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| BR112014018657B1 (pt) | 2012-02-21 | 2022-08-02 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Compostos de 1h-indazol-3-carboxamida |
| AU2013224302B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| WO2017201585A1 (en) | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| ES2902995T3 (es) * | 2016-10-07 | 2022-03-30 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| DK3704118T3 (da) | 2017-10-30 | 2022-03-14 | Bristol Myers Squibb Co | Aminoimidazopyrazin som kinasehæmmere |
| SG11202007035YA (en) | 2018-01-26 | 2020-08-28 | Bristol Myers Squibb Co | Aminopyrrolotriazines as kinase inhibitors |
| EP3849968B1 (en) | 2018-09-13 | 2022-12-21 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| EP3849969B1 (en) | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| WO2021067654A1 (en) | 2019-10-03 | 2021-04-08 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
-
2019
- 2019-09-12 EP EP19779242.7A patent/EP3849969B1/en active Active
- 2019-09-12 MX MX2021002617A patent/MX2021002617A/es unknown
- 2019-09-12 BR BR112021004310-1A patent/BR112021004310A2/pt not_active Application Discontinuation
- 2019-09-12 SG SG11202102406XA patent/SG11202102406XA/en unknown
- 2019-09-12 CA CA3112519A patent/CA3112519A1/en active Pending
- 2019-09-12 KR KR1020217010495A patent/KR102793119B1/ko active Active
- 2019-09-12 EA EA202190759A patent/EA202190759A1/ru unknown
- 2019-09-12 JP JP2021513960A patent/JP7434294B2/ja active Active
- 2019-09-12 US US17/274,227 patent/US12084426B2/en active Active
- 2019-09-12 CN CN201980059544.6A patent/CN112673001B/zh active Active
- 2019-09-12 WO PCT/US2019/050721 patent/WO2020056074A1/en not_active Ceased
- 2019-09-12 ES ES19779242T patent/ES2945220T3/es active Active
- 2019-09-12 AU AU2019339355A patent/AU2019339355A1/en not_active Abandoned
-
2021
- 2021-03-09 IL IL281371A patent/IL281371A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501334A5 (enExample) | ||
| JP2022512156A5 (enExample) | ||
| JP2016513661A5 (enExample) | ||
| JP2007519694A5 (enExample) | ||
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| JP2020527173A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2017537948A5 (enExample) | ||
| JP2016507502A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| RU2007119562A (ru) | Тетрациклические производные индолов в качестве противовирусных агентов | |
| JP2012508252A5 (enExample) | ||
| RU2012156940A (ru) | Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2023504542A5 (enExample) | ||
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| IL175609A (en) | N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed | |
| RU2010106854A (ru) | Производные 2-аза-бицикло[3.3.0]октана | |
| JP2022553077A5 (enExample) | ||
| RU2010145463A (ru) | Производные замещенного 2-фенилпиридина | |
| JP2010527985A5 (enExample) | ||
| JP2022500418A5 (enExample) | ||
| JP2022533939A5 (enExample) | ||
| WO2007132228A1 (en) | Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder | |
| JP2018507257A5 (enExample) | ||
| JP2023531495A5 (enExample) |